Stay updated with breaking news from Stimulating Agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The renal anemia therapeutics market is estimated to grow by USD 2.08 billion during 2023-2028, growing at a CAGR of 7.59%. Akebia Therapeutics...
Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India.
Hyporesponse to erythropoiesis-stimulating agents was associated with increased rates of red blood cell transfusions and poorer outcomes in patients with chronic kidney disease, highlighting the need for alternative anemia treatments.
According to Coherent Market Insights, Global Cancer supportive care products Market is estimated to be valued at US$ 32,458.0 million in 2023 and is expected
Seattle, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic kidney disease drugs market is estimated to be...